ArticleMedicine2026
Identification of COL5A1 and TGFBI as key basement membrane genes and their molecular mechanisms in gestational diabetes mellitus.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes mellitus (GDM) is a common complication during pregnancy, but the role of the basement membrane (BM) in GDM is not well understood. This study aims to investigate BM-related genes in GDM to provide new insights for diagnosis and treatment. Differentially expressed genes were identified from the GSE203346 dataset in the Gene Expression Omnibus and intersected with BM-related genes to identify BM-related differential genes. Machine learning and gene expression validation were used to identify key genes, which were further validated using an artificial neural network. Additional analyses included gene set enrichment analysis, immunoprecipitation, drug prediction, gene localization, and the construction of lncRNA-miRNA-mRNA and transcription factor-mRNA regulatory networks to explore underlying mechanisms. Among 801 differentially expressed genes, 24 BM-related differential genes were identified. COL5A1, TGFBI, AGRN, TNC, and ITGB6 were identified as candidate genes, with COL5A1 and TGFBI showing consistent low expression across datasets and being designated as key genes. The artificial neural network demonstrated that these key genes effectively distinguished GDM from control samples. Gene set enrichment analysis revealed the involvement of these genes in pathways such as systemic lupus erythematosus and cytokine-cytokine receptor interaction. TGFBI showed a significant positive correlation with CD4+ memory T cells, common lymphoid progenitors, hematopoietic stem cells, and smooth muscle, while COL5A1 was positively correlated with common lymphoid progenitors and smooth muscle. Six drugs were identified as interacting with both key genes. Our study suggests that COL5A1 and TGFBI offer the possibility of personalized treatment strategies for GDM in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.